Thanks for posting that, docj. I was glad to read this part...

"Patients completing study CD-O-101 will be given the option to enter a rollover study where they can continue to receive leronlimab. Patients who have progressed on the parent study will also be offered treatment with leronlimab in combination with an immune checkpoint inhibitor."